Lexeo Therapeutics, Inc. filed an 8-K with the SEC on September 22, 2026, disclosing that it entered into an Agreement and Plan of Merger with Mantle Therapeutics Inc. on September 16, 2026, under which Mantle would become a wholly owned subsidiary of Lexeo.
Key Highlights
- Upfront cash consideration: Mantle stockholders are entitled to receive an aggregate upfront cash payment of $5,300,000, subject to certain adjustments.
- Upfront stock consideration: An additional $3,000,000 in shares of Lexeo common stock will be issued at closing, not registered under the Securities Act of 1933.
- Contingent milestone payments: Up to an aggregate of $12,000,000 may become payable upon specified development and regulatory milestones over a 12-year milestone term.
- Additional contingent cash payment: A one-time aggregate cash payment of $1,000,000 is payable only upon achievement of certain unspecified events.
- Key Stockholder support: Stockholders holding approximately 76.1% of outstanding Mantle capital stock and approximately 83.5% of Mantle preferred stock have signed voting and support agreements in favor of the merger.
- Termination deadline: Either party may terminate the Merger Agreement if the transaction has not closed by November 16, 2026.
- CLARITY-FA study update: The company announced that 22 participants are enrolled or imminently enrolling in its CLARITY-FA study.
Lexeo-Mantle Merger Terms, Conditions, and Contingent Payments
According to the filing, Lexeo Therapeutics, Inc. (NASDAQ:LXEO), headquartered at 345 Park Avenue South, Floor 6, New York, New York 10010, entered into the Merger Agreement on September 16, 2026. Under the agreement, Magma Merger Sub Inc., a wholly-owned subsidiary of Lexeo, will merge with and into Mantle Therapeutics Inc., with Mantle surviving as a wholly owned subsidiary of Lexeo. Shareholder Representative Services LLC, a Colorado limited liability company, is named as representative of the sellers.
At the effective time of the merger, the filing discloses, each outstanding share of Mantle capital stock (excluding treasury shares, shares held by Lexeo or Merger Sub, and dissenting shares) will convert into the right to receive the upfront consideration of $5,300,000 in cash and $3,000,000 in Lexeo common stock. Mantle restricted stock will vest in full and be cancelled immediately prior to closing for the same consideration, subject to withholding. Outstanding SAFEs will be cancelled in exchange for applicable SAFE consideration under each instrument's liquidity event provisions, and convertible promissory notes will be cancelled upon payment of the applicable payoff amount. The filing states that the common stock issued at closing will be issued in reliance on the exemption from Securities Act registration provided by Section 4(a)(2) and/or Regulation D.
The Merger Agreement also provides for up to $12,000,000 in milestone payments payable over 12 years upon specified development and regulatory milestones relating to Mantle's product candidates, with certain payments in cash and certain in Lexeo common stock valued using a thirty-day trailing volume-weighted average price. The filing states that "Lexeo makes no guarantees that it will achieve any milestone." Closing is conditioned on, among other things, receipt of requisite stockholder approval, accuracy of representations and warranties, and the absence of a material adverse effect. On September 22, 2026, the company also separately announced that it has 22 participants enrolled or imminently enrolling in its CLARITY-FA study.
What Was Disclosed
Lexeo Therapeutics disclosed the execution of a merger agreement to acquire Mantle Therapeutics for upfront consideration of $5,300,000 in cash and $3,000,000 in stock, plus contingent payments of up to $13,000,000 tied to milestones and specified events, with closing targeted before November 16, 2026.



Please wait processing your request...